Every one of those 1 sits in a single category, pharma. ATG-022 is most often covered alongside ATG-207, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. ATG-022 appears in 1 tracked Biotech story from August 23, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about ATG-022
Every one of those 1 sits in a single category, pharma. ATG-022 is most often covered alongside ATG-207, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. ATG-022 appears in 1 tracked Biotech story from August 23, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 2 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering ATG-022. Shared-story counts are live from our verified record — not editorial picks.
For biotech and pharma professionals, Antengene's showcase demonstrates platform depth in T-cell engager engineering, adding TriGager to its AnTenGager toolbox and introducing a first-in-class αCD3-TGF-β fusion protein. The presentation also included updated ATG-022 data, though no quantitative results were disclosed. This positions Antengene as a company to watch in the crowded CLDN18.2 and TCE arenas.
